Home » Market News » DirectorsTalk Highlights » Motif Bio Plc – Vadim Alexandre of Northland Capital discusses Trial Supplies
Motif Bio Plc

Motif Bio Plc – Vadim Alexandre of Northland Capital discusses Trial Supplies

Motif Bio Plc (LON:MTFB) – is the topic of discussion when Vadim Alexandre of Northland Capital caught up with DirectorsTalk. Vadim discusses the new trial supplies milestone reached and the impact this has on Motif’s clinical programme.

Motif Bio the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites. These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017.

Motif Bio Plc is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistantStaphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.  For additional information about Motif please visit www.motifbio.com.


Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.